Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir and Ribavirin in HCV Genotype 3 Decompensated Cirrhosis
NCT02464631Terminated
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sofosbuvir in hepatitis C virus infection (3 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Sustained Virologic Response at 24 weeks post-treatment. Started Jun 2015; status: terminated.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02464631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464631.